GTx, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of medicines for the treatment of stress urinary incontinence (SUI) and prostate cancer. It focuses on the development of selective androgen receptor modulators (SARMs) for the treatment of breast cancer, SUI, and Duchenne muscular dystrophy; and selective androgen receptor degraders to treat progressive castration-resistant prostate cancer. The company's lead SARM candidate is the enobosarm GTx-024, a Phase II open-label proof-of-concept clinical trial for patients with androgen receptor (AR) positive triple-negative breast cancer; and estrogen receptor positive and AR positive advanced breast cancer, as well as postmenopausal women with SUI. GTx, Inc. was founded in 1997 and is headquartered in Memphis, Tennessee.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Phone901-523-9700
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees27
Next Earnings Date3/11/2019 (Estimated)
OptionableOptionable
GTX (NASDAQ:GTXI) Frequently Asked Questions
What is GTX's stock symbol?
GTX trades on the NASDAQ under the ticker symbol "GTXI."
How were GTX's earnings last quarter?
GTx, Inc. (NASDAQ:GTXI) announced its quarterly earnings data on Thursday, November, 15th. The biopharmaceutical company reported ($0.39) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.30) by $0.09. View GTX's Earnings History.
When is GTX's next earnings date?
What price target have analysts set for GTXI?
2 Wall Street analysts have issued 1-year target prices for GTX's stock. Their predictions range from $17.00 to $45.00. On average, they anticipate GTX's stock price to reach $31.00 in the next year. This suggests a possible upside of 2,824.5% from the stock's current price. View Analyst Price Targets for GTX.
What is the consensus analysts' recommendation for GTX?
2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for GTX in the last year. There are currently 2 hold ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for GTX.
Has GTX been receiving favorable news coverage?
Media coverage about GTXI stock has trended somewhat positive on Saturday, InfoTrie Sentiment Analysis reports. The research firm identifies negative and positive media coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. GTX earned a news sentiment score of 1.7 on InfoTrie's scale. They also gave news coverage about the biopharmaceutical company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an effect on the company's share price in the next few days.
Who are some of GTX's key competitors?
Some companies that are related to GTX include Pharmaxis (PXSLY), Alpine Immune Sciences (ALPN), Teligent (TLGT), Provention Bio (PRVB), Merrimack Pharmaceuticals (MACK), Iterum Therapeutics (ITRM), AVEO Pharmaceuticals (AVEO), VERONA PHARMA P/S (VRNA), Medicure (MCUJF), PhaseBio Pharmaceuticals (PHAS), Tiziana Life Sciences (TLSA), Avadel Pharmaceuticals (AVDL), Entasis Therapeutics (ETTX), Melinta Therapeutics (MLNT) and Alimera Sciences (ALIM).
What other stocks do shareholders of GTX own?
Who are GTX's key executives?
GTX's management team includes the folowing people:
- Dr. Robert James Wills Ph.D., Exec. Chairman (Age 65)
- Mr. Marc S. Hanover, Co-Founder, CEO & Director (Age 56)
- Mr. Henry P. Doggrell, VP, Chief Legal Officer & Sec. (Age 70)
- Mr. Jason T. Shackelford, VP of Fin. & Accounting, Principal Financial & Accounting Officer and Corp. Controller (Age 44)
- Dr. Diane C. Young, VP & Chief Medical Officer (Age 62)
Who are GTX's major shareholders?
GTX's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (1.93%), Geode Capital Management LLC (0.94%), Bank of America Corp DE (0.85%), Two Sigma Investments LP (0.55%), GSA Capital Partners LLP (0.45%) and Virtu Financial LLC (0.28%). Company insiders that own GTX stock include Diane C Young, Henry Patton Doggrell, Jason T Shackelford, Marc Steven Hanover and Robert James Wills. View Institutional Ownership Trends for GTX.
Which institutional investors are selling GTX stock?
GTXI stock was sold by a variety of institutional investors in the last quarter, including Geode Capital Management LLC and BlackRock Inc.. Company insiders that have sold GTX company stock in the last year include Diane C Young, Henry Patton Doggrell and Jason T Shackelford. View Insider Buying and Selling for GTX.
Which institutional investors are buying GTX stock?
GTXI stock was bought by a variety of institutional investors in the last quarter, including Bank of America Corp DE, GSA Capital Partners LLP, Virtu Financial LLC, Two Sigma Advisers LP and Two Sigma Investments LP. View Insider Buying and Selling for GTX.
How do I buy shares of GTX?
Shares of GTXI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is GTX's stock price today?
One share of GTXI stock can currently be purchased for approximately $1.06.
How big of a company is GTX?
GTX has a market capitalization of $25.50 million. The biopharmaceutical company earns $-30,430,000.00 in net income (profit) each year or ($1.75) on an earnings per share basis. GTX employs 27 workers across the globe.
What is GTX's official website?
How can I contact GTX?
GTX's mailing address is 175 TOYOTA PLAZA 7TH FLOOR, MEMPHIS TN, 38103. The biopharmaceutical company can be reached via phone at 901-523-9700 or via email at [email protected]
MarketBeat Community Rating for GTX (NASDAQ GTXI)
MarketBeat's community ratings are surveys of what our community members think about GTX and other stocks. Vote "Outperform" if you believe GTXI will outperform the S&P 500 over the long term. Vote "Underperform" if you believe GTXI will underperform the S&P 500 over the long term. You may vote once every thirty days.
